JNCCN 360 – CML – Link Between Cognitive Impairment and Outcomes in Older Recipients of Allogeneic HCT?

By: Lauren Harrison, MS Posted: Friday, August 21, 2020 Cognitive impairment appears to be associated with inferior overall survival by increasing the nonrelapse mortality in patients who received allogeneic hematopoietic stem cell transplantation (alloHCT) for treatment of CML. Andrew Artz, MD, MS, of the…

Read the full article here

Source: jnccn360.org

Categories: Hem/Onc News and Journals, Latest Headlines

Tags: CML, cognitiveimpairment, gerionc, HCT, JNCCN360, leusm

Tweets with this article

Journal of the @NCCN

Is there a link between #cognitiveimpairment and outcomes in older patients with #CML who undergo allogeneic #HCT? https://t.co/lG3mtuiWk7 #leusm #JNCCN360 #GeriOnc https://t.co/vZ4IDscqQu

Related Articles

JNCCN 360 – Advanced Skin Cancers – Michael K.K. Wong, PhD, MD, on Early Results on Navtemadlin, a Novel MDM2 Inhibitor, for Merkel Cell Carcinoma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Tina J Hieken MD April 12, 2024

JNCCN 360 – Breast – Australian Study Investigates Who May Safely Omit Postoperative Radiotherapy for Early Breast Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN April 12, 2024

JNCCN 360 – Breast – Study Identifies Novel Therapeutic Targets for Males With Breast Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN April 12, 2024

JNCCN 360 – Advanced Skin Cancers – Anti–PD-L1 Refractory Melanoma: Combining Tyrosine Kinase and PD-1 Inhibitors

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN April 12, 2024

JNCCN 360 – Prostate – More FORMULA-509 Results After Radical Prostatectomy: Quality-of-Life Outcomes

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN April 12, 2024

JNCCN 360 – Advanced Skin Cancers – Anti–PD-L1 Refractory Melanoma: Combining Tyrosine Kinase and PD-1 Inhibitors

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN April 11, 2024

JNCCN 360 – MM – Novel Treatments for Multiple Myeloma May Emerge From Ephrin B2 Research

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN April 11, 2024

JNCCN 360 – Breast – Copper-Related Genes and Response to Trastuzumab in HER2-Positive Disease

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN April 10, 2024

JNCCN 360 – Non–Small Cell Lung Cancer – (NEW Update) Nivolumab in NSCLC

Posted: Thursday, April 4, 2024 The U.S. Food and Drug Administration (FDA) first approved nivolumab (Opdivo) to treat metastatic squamous non–small cell lung cancer (NSCLC)…

Journal of the @NCCN April 10, 2024

JNCCN 360 – MM – Relationship Between Age and Outcomes in Multiple Myeloma: A View From Latin America

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN April 5, 2024